PAG
GILD icon

Paladin Advisory Group’s Gilead Sciences GILD Stock Holding History

Paladin Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-132
Closed -$10.2K – 264
2023
Q2 		$10.2K Hold
132
– – 0.01% 216
2023
Q1 		$11K Buy
+132
New +$10.9K 0.01% 215
2022
Q2 		– Sell
-208
Closed -$12.9K – 360
2022
Q1 		$12K Buy
+208
New +$13.3K 0.01% 224

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Paladin Advisory Group's GILD Position: Q3 2023 in Review

Paladin Advisory Group sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 132 shares — an estimated $10.2K sold.

Paladin Advisory Group first reported a position in GILD in Q1 2022 and held it in 3 quarters. The position peaked at $12K in Q1 2022. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • Paladin Advisory Group reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
  • Paladin Advisory Group sold 132 Gilead Sciences shares in Q3 2023, an estimated $10.2K.
  • Paladin Advisory Group first reported a position in Gilead Sciences in Q1 2022 and held it in 3 quarters.
  • Paladin Advisory Group's Gilead Sciences position peaked at $12K in Q1 2022.
  • 1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Paladin Advisory Group's 13F filing for Q3 2023, filed 17 Oct 2023.